RxDoctor Payments Data

Robert Stewart

Psychiatry · Louisville, KYNPI 1750423034

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $562,962 of the $651,061 with a category attached, or 86.5%. AbbVie accounts for 75.2% of it on its own, with 33 other manufacturers making up the rest. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$651,061in general payments, 2019–2025

Across 1,349 payments — averaging $482.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$490K
  • Axsome Therapeutics, Inc.$54K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$31K
  • Vanda Pharmaceuticals Inc.$28K
  • Otsuka America Pharmaceutical, Inc.$27K
  • Takeda Pharmaceuticals U.S.A., Inc.$12K
  • plus $9K from 28 others

What the payments were for

  • Consulting fees$36,7506%
  • Speaking & faculty fees$562,96286%
  • Travel & lodging$32,5065%
  • Food & beverage$18,6643%
  • Education$1790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$651,061 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$109,740
CaplytaLumateperone Tosylate19$42,853
TrintellixVortioxetine Hydrobromide44$29,832
AuvelityDextromethorphan Hbr/Bupropion20$26,134
QuviviqDaridorexant Hcl24$12,540
Lurasidone Hcl36$7,858
VyvanseLisdexamfetamine Dimesylate17$7,346
Lisdexamfetamine Dimesylate16$6,890
Asenapine Maleate19$4,155
Modafinil28$3,521
Bupropion Hcl SrBupropion Hcl128$3,095
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine85$3,065
Divalproex Sodium ErDivalproex Sodium46$2,777
Zolpidem Tartrate ErZolpidem Tartrate31$2,767
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$2,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$134$109,74013 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$31,402$42,85319 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$11,944$37,17861 claims
Axsome Therapeutics, Inc.Auvelity$54,482$26,13420 claims
Idorsia Pharmaceuticals US IncQuviviq$3,587$12,54024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →